Cart
sales@molnova.com
(-)-Hinokinin
CAS No. 26543-89-5
(-)-Hinokinin( —— )
Catalog No. M31238 CAS No. 26543-89-5
(-)-Hinokinin has anti-genotoxic and anticarcinogenic potential.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 475 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(-)-Hinokinin
-
NoteResearch use only, not for human use.
-
Brief Description(-)-Hinokinin has anti-genotoxic and anticarcinogenic potential.
-
Description(-)-Hinokinin has anti-genotoxic and anticarcinogenic potential. (-)-Hinokinin is an anti-chagasic drug, has no mutagenic effects in animal cell and bacterial systems, anxiety that target the DAT, NET, and GAT-1 transporters, it may serve as a tool to develop new therapeutic drugs for attention deficit hyperactivity disorder.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number26543-89-5
-
Formula Weight354.4
-
Molecular FormulaC20H18O6
-
Purity>98% (HPLC)
-
SolubilityDMSO, Pyridine, Methanol, Ethanol, etc.
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.J Nat Prod. 2013 Oct 25;76(10):1889-95.
molnova catalog
related products
-
Brr2 Inhibitor C9
Brr2 inhibitor C9 is an allosteric inhibitor of the spliceosomal RNA helicase Brr2. Brr2 is implicated in autosomal-dominant retinitis pigmentosa (a group of progressive retinal degenerative disorders).
-
1,2-Dilauroyl-sn-gly...
Diacylglycerols are primarily composed of the interaction of 1,2-dilauroyl-sn-glycerol (1,2-DLG) with phosphatidylcholine (PC) bilayers.
-
β-CGRP, human TFA
β-CGRP,human tissue is one of the calcitonin peptide, through complex behavior of calcitonin receptor like receptor (CRLR) - and receptor activity - modifying proteins (increased), and 1 and 300 - nM CRLR IC50s/RAMP1 and CRLR/RAMP2 cells.
